Background. National VL Elimination Programs in India, Nepal and Bangladesh face challenges as home-based Miltefosine treatment is introduced. Objectives. To study constraints of VL management in endemic districts within context of national elimination programs before and after intervention. Methods. Ninety-two and 41 newly diagnosed VL patients were interviewed for clinical and provider experience in 2009 before and in 2010 after intervention (district training and improved supply of diagnostics and drugs). Providers were assessed for adherence to treatment guidelines. Facilities and doctor-patient consultations were observed to assess quality of care. Results. Miltefosine use increased from 33% to 59% except in Nepal where amphotericin was better available. Incorrect dosage and treatment interruptions were rare. Advice on potential side effects was uncommon but improved significantly in 2010. Physicians did not rule out pregnancy prior to starting Miltefosine. Fever measurement or spleen palpation was infrequently done in Bangladesh but improved after intervention (from 23% to 47%). Physician awareness of renal or liver toxicity as Miltefosine side effects was lower in Bangladesh. Bio-chemical monitoring was uncommon. Patient satisfaction with services remained low for ease of access or time provider spent with patient. Health facilities were better stocked with rK39 kits and Miltefosine in 2010.
Introduction
Visceral Leishmaniasis (VL) or Kala-azar has a high-disease burden in endemic districts of the Indian subcontinent (annual VL incidence ranging from 9/10,000 in Nepal to 30/10,000 pop. in India and Bangladesh) [1] . These VL endemic countries have adopted a range of public health strategies towards the elimination goal of reducing VL cases to less than 1/10,000 population by 2015 [2] . Kala-azar Elimination Programs (KAEP) aim to reduce VL morbidity and mortality by early detection, diagnosis, and treatment of VL through strengthening diagnostic and treatment facilities at peripheral health care institutions and referral services. These coupled with integrated vector management strategies including indoor residual spraying, promotion of use of insecticide treated bed nets aim to reduce VL transmission and disease burden. Despite efforts, disease transmission continues. Early detection is hindered by a surveillance 2 Journal of Tropical Medicine system which is primarily dependent on passive reporting of patients to a public health facility. Surveillance systems rarely capture VL cases treated in the private sector. Furthermore PKDL cases escape detection through routine surveillance and contribute to continued transmission of the disease in the community [3] . Many VL cases go undiagnosed in a web of unqualified medical practitioners before they are finally diagnosed and treated for VL in the qualified private or public health sector leading to considerable delays in diagnosis and treatment [1, 4] . Recent studies show that active case detection strategies increase early VL detection and reduce delays to diagnosis and treatment [5, 6] . Early diagnosis is now feasible with the increasing use of fieldbased rapid diagnostic tests (rK39) to detect antibodies to recombinant antigen rK39 which are highly sensitive (range 98%-99%) and specific (range 96%-97%) [7] . Drugs available for VL treatment are limited with no new drugs under development. Historically, antimonials have been the primary line of treatment but now face emerging problems of drug resistance. Amphotericin B deoxycholate used more often as a secondary line of treatment for VL cases responding poorly to antimonials requires prolonged hospitalization and repeated biochemical monitoring. Miltefosine, the only oral drug for VL, has been recently favoured as it is highly effective (94% cure rate) with minimal side effects [8] [9] [10] [11] . Recent research has shown single-dose liposomal Amphotericin B as well as combination drug therapy to be highly effective and safe but it will take some years before it can be adopted by country control programs.
WHO TDR has supported a research program to determine disease burden, identify, and test strategies for early detection and treatment of VL since 2006. In 2009 (preintervention phase), researchers identified VL patients using active case detection strategies. In 2010, Kala-azar Elimination Program (KAEP) staff was trained in these strategies and in VL case management according to national guidelines [12] [13] [14] accompanied by an increased procurement of diagnostics and drugs through the national program. This paper looks at the pre-and postintervention prospects and constraints of VL management from a patient and provider perspective in VL endemic districts of India, Nepal, and Bangladesh within the context of KAEP activities. 
Material and Methods

Ethics
Identifying New Cases of VL and Training for Improved
Application of National Treatment Guidelines; Preintervention and Program Intervention Phase. In 2009 (preintervention phase), four active case detection strategies (camp approach, index case approach-focal house search around known VL case, incentive approach, and blanket approach-house-tohouse search) were assessed for yield of new VL cases by researchers [6] . The most cost-effective of these active case detection strategies (camp approach in high VL endemic areas and index case approach in low-to-moderate VL endemic areas) was presented to the intercountry Regional Technical Advisory Group (RTAG) and then introduced as part of the VL elimination program in 2010. Standard Operating Procedures were developed and program managers, doctors, and health workers were trained and supported by the researchers in the planning of these active case detection strategies. A total of 243 health staff was trained across all sites in active case detection strategies and VL case management as per country guidelines. The health system adopted these active case detection strategies to identify new VL cases in 2010 and reinforced the procurement of VL diagnostics and drugs in peripheral health facilities while the training program-jointly developed by national program managers and the research team and supported by German cooperation (Federal Ministry for Economic Cooperation and Development (BMZ)/Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH-focussed at the correct application of national treatment guidelines (program intervention package). A total of 126 health workers and volunteers in India, 91 in Nepal, and 26 in Bangladesh were trained in active case detection strategies and home-based VL case management.
As per the research protocol, all newly identified VL patients through active case detection in 2009 who were treated with Miltefosine were interviewed by researchers at the end of their treatment for their clinical experience, their interaction and experiences with providers using a standardized pretested questionnaire. The Indian site additionally chose to interview newly identified VL patients treated with other than Miltefosine. Whereas in 2010, all newly identified VL patients were interviewed irrespective of their drug treatment by all sites. We compare treatment patterns and patient perspectives before and after the intervention.
Patient satisfaction with provider care was rated on a 5-point scale using a shortened 18-item version of the Patient Satisfaction Questionnaire (PSQ-18) [15] . Patient satisfaction mean score (range 1 to 5) in several domains was derived with high scores reflecting high satisfaction levels. Additionally, interactions between patients and providers were directly observed in a structured manner by researchers wherever feasible.
Providers were also interviewed with a standardized questionnaire to assess their knowledge and experiences of treating VL, adherence to treatment guidelines and their perception of home treatment with Miltefosine. Health facilities were assessed (structured spot inspection) for availability of diagnostic kits and drugs, records and equipment required to treat VL and side effects.
We compare means and proportions for various patient and provider characteristics for differences seen in 2009 and 2010 separately for each site. Due to small samples of VL patients and providers, we used Fischer's exact test to test for significance of differences not disaggregated by site.
Results
A total of 92 (India-63; Nepal-8; Bangladesh-21) new VL patients were identified through these active case detection strategies (camps, focal search around index case, etc.) in 2009 and 41 (India-8; Nepal-20; Bangladesh-13) in 2010. Thirteen newly diagnosed VL patients in 2009 from Bangladesh were thought to be cases of VL relapse and were referred to the district hospital for further treatment. We were not able to ascertain the treatment status of these patients as they were lost to follow-up. Patients were significantly younger (mean age 22 years, SD-16.47) in 2010 compared to 33 years (SD-15.9) in 2009 (P value = 0.009). The proportion of women was significantly higher (32% in 2010 compared to 8% in 2009; P value = 0.027).
VL Patient Experiences: Preintervention and Program
Intervention Phase. Overall, the proportion of VL patients treated with Miltefosine as 1st line of treatment increased from 33% in 2009 to 59% in 2010 (Table 1) Despite Miltefosine being available free of cost to the patient through the program, 12% of the health workers interviewed in Bangladesh perceived the cost of VL treatment to be affordable, while 18% perceived it to be too high. A majority of health staff felt that lack of patient awareness and lack of access to facility (100% in India; 82% in Bangladesh) were major challenges to early detection and diagnosis of VL.
Drug shortage and lack of patient compliance were perceived by health workers to be major barriers to VL treatment in India. About half of all health workers in India and Bangladesh reported cost as a barrier to VL treatment. In India, 64% of health workers reported occurrence of drugrelated side effects as a problem for VL treatment compared to 18% of health workers in Bangladesh.
Discussion
In the preintervention phase (2009), VL patients were diagnosed using rK39 tests conducted by the researchers. These newly diagnosed VL cases were then referred to health centers and their further treatment was ensured by the researchers. In contrast, in 2010, the researchers' role was restricted to training of trainers in the health system in home-based VL management with Miltefosine applying national treatment guidelines. Diagnosis and home-based treatment of VL cases under direct observation of a health functionary or volunteer in 2010 was fully the responsibility of the health system (program intervention phase). The researchers assessed the availability of diagnostics and drugs in peripheral health facilities and evaluated VL case management as implemented by the health system.
The use of antimonials showed a dramatic decline in 2010 as preference shifted towards Miltefosine as the primary line of VL treatment-in Bangladesh, this shift was consequent to introduction of Miltefosine in the country while in India it was more due to its availability in the public sector at no cost to the patient. In Nepal, at the time of the study Amphotericin B continued to be used as the drug of choice for VL treatment in 2010 as one of the district hospital had to dispense a large stock before its expiry. Also, Amphotericin B was preferred by physicians at one of the zonal hospitals.
The shift towards Miltefosine was paralleled by an increase in the known side effects of Miltefosine (diarrhea and vomiting) but a decrease in side effects from antimonials (not documented in this study). Almost all patients received the correct dosage schedule in both study phases indicating correct prescription practices and a high level of knowledge about drug dosage and schedules amongst physicians. Treatment was interrupted in less than 5% of patients in either phase (in one patient due to drug shortage). Miltefosine dosage schedule is based on the patient's age and body weight. Its use is contraindicated in infants, pregnant, or breast-feeding women or women of reproductive age group unless counselled to prevent pregnancy with use of oral contraceptives [12] . A pregnancy test is also generally recommended to rule out pregnancy prior to Miltefosine use. Medical supervision is advised twice a week and monitoring for hepatic and renal function is recommended wherever feasible according to national guidelines. Counselling for need to comply with full treatment seemed to be adequate in both study phases. Counselling for need to follow up weekly during treatment was lower in 2009 but increased in the postintervention phase especially in India. Counselling of patients on potential side effects was still inadequate and needs to be strengthened. Only about 1 in 6 physicians in Nepal ruled out pregnancy on history in women of reproductive age. Pregnancy test or contraceptive counselling was not done for any woman of reproductive age prior to Miltefosine use. The quality of care given by providers was inadequate. Fever was measured in less than half of initial or follow-up visits in Nepal and Bangladesh. Spleen size was assessed by palpation in less than half of initial or followup visits in Bangladesh. Blood tests (biochemical monitoring before and during treatment) were advised in less than half of all initial or follow-up visits in Nepal and Bangladesh. Monitoring of side effects during follow-up visits was almost universal in the postintervention phase. Though there was a significant improvement in patient satisfaction levels in the postintervention phase, patients were less satisfied with ease of access to provider and the time spent by the provider with them. Generally patients in India were more satisfied with how providers communicated with them as well as their manners and attitudes in the postintervention phase compared to patients in Nepal and Bangladesh. However, these differences in satisfaction levels could be cultural based on patient's experiences and expectations of health services. Overall, health facilities were better stocked with rK39 diagnostic kits and VL drugs in 2010 except in Bangladesh where 3 of the 4 health facilities inspected did not have rK39 diagnostic kits. Drug supply was available and adequate in health facilities in India. Amphotericin B as 2nd line of treatment was not available in more than half of all health facilities in India and Nepal and not at all available in Bangladesh. Drug supply needs to be strengthened especially in Nepal and Bangladesh. The maintenance of patient specific treatment cards needs to be strengthened at all health facilities in each country.
In summary, physician counselling practices requires to be strengthened. Despite availability, about one-third of physicians (especially in the private sector) in India still rely on tests other than rK39 for VL diagnosis. Physician choice is driven by the availability of the drug and its perceived safety and less so by affordability or effectiveness of the drug. Ensuring an adequate drug supply will greatly influence physician prescription practice for VL. Physician awareness of the common side effects of Miltefosine like diarrhea and vomiting is high. However, awareness about important but less common side effects of Miltefosine like liver and renal toxicity is low especially in Bangladesh and needs to be improved. Testing blood for haemoglobin, liver, and renal function before and during VL treatment is still not routine practice with physicians in India and Bangladesh. Improving physician awareness of potential side effects of Miltefosine and ensuring availability of laboratory services will strengthen physician practice of routine bio-chemical monitoring before and during VL treatment. National guidelines stipulate that Miltefosine can be administered at home under direct supervision of a health volunteer/health functionary. Though almost all physicians in India, Nepal, and Bangladesh feel that home-based treatment of VL with Miltefosine is effective, only about half the physicians in Nepal would recommend it.
Conclusion
Though limited by small samples of patients interviewed and doctor-patient consultations observed and health facilities inspected, our study provides evidence on constraints and prospects of VL management in VL endemic districts of India, Nepal, and Bangladesh when implemented by national VL elimination programs. This underlines the need 
